Introduction New generation biologics, including interleukin (IL)-17 and IL-23 inhibitors,
have delivered higher rates of skin clearance than older treatments in head-to-head studies …

Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation …

In times of targeted therapies, innovative therapeutics become tools to further unravel the
pathogenesis of the treated disease, thus influencing current pathogenetic concepts. Based …

Background Patients with plaque psoriasis treated with biologic therapies need more
efficacious, safe and convenient treatments to improve quality of life. Risankizumab and …

Background Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin
(IL)‐17A and IL‐17F, which is currently under investigation for treatment of moderate‐to …

Introduction Risankizumab has been approved for the treatment of moderate-to-severe
plaque psoriasis; however, real-life data are limited. Our objectives were to evaluate the …

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic disabling and
debilitating inflammatory disease with a high unmet medical need. The prevalence of HS …

Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are both chronic, inflammatory
conditions that result in a substantial burden of disease and reduced quality of life for …

Background Risankizumab and guselkumab, inhibitors of the interleukin (IL)-23 p19 subunit,
are approved for treatment of adult patients with moderate-to-severe plaque psoriasis, and …

Objectives To describe the results of a structured literature review of real-world outcomes
with ixekizumab in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). Methods …